In August 2026, a remarkable story unfolded in Indian markets.
The sovereign wealth fund had deployed nearly $9 billion in India over the past three years, emerging as a consistent net buyer when others were heading for the exits.
The results speak for themselves. Four Temasek-backed companies listed with spectacular debuts: Shiprocket at 35% premium, Milky Mist at 40% premium within a day, Molbio Diagnostics at 26% premium, and Manipal Health at 25% premium. India became Temasek's best-performing market on a 10-year basis, with its exposure growing four-fold to $42 billion.
So what did Temasek see that others missed? And how did it execute this contrarian strategy so effectively?
The divergence stems from fundamentally different investment philosophies. When Bank of America's August 2026 survey identified India as Asia's least-preferred market—citing lack of AI exposure, weak growth, slow reforms, and high valuations—Temasek was looking at a different set of metrics.
"We were a net buyer of listed Indian equities during the past financial year, using periods of market volatility to add selectively to high-conviction positions," a Temasek spokesperson told CNBC. This approach reflects a focus on structural trends rather than cyclical noise.
The currency impact matters too. While the Nifty 50 was down 7.9% in rupee terms from December 2025 to August 19, 2026, it fell 13.6% in dollar terms due to rupee depreciation. Global fund managers get paid in dollars, so they see a 14% loss. Temasek, with its permanent capital and long-term horizon, can look through currency volatility to focus on business fundamentals.
Temasek's conviction rests on four powerful structural drivers: a large domestic consumer market, growing middle class, economic formalization, and infrastructure build-out. These factors create a growth story that transcends short-term market cycles.
India's GDP is forecast to grow 6.5-6.9% in FY26, making it one of the fastest-growing major economies globally. The middle class is expanding rapidly, with OECD forecasts predicting India will overtake China in middle-class population between 2030 and 2035. This demographic shift drives consumption and creates a deep domestic market that's relatively insulated from global volatility.
The formalization trend is equally compelling. GST collections reached ₹1.81 lakh crore in July 2026, up 15.8% year-on-year, reflecting improved compliance and economic organization. This creates opportunities for organized sector players across industries.
Temasek's India portfolio spans consumer, logistics, healthcare, financial services, and increasingly, industrials, infrastructure, and renewables. This diversification isn't random—it's a deliberate strategy to mitigate sector-specific risks while capturing multiple growth themes.
The consumer sector, represented by Milky Mist, benefits from rising incomes and the shift from unorganized to organized players. Logistics, through Shiprocket, plays on e-commerce growth and supply chain digitization. Healthcare investments in Molbio Diagnostics and Manipal Health tap into the "longer lifespans" structural trend.
But Temasek is expanding beyond these traditional focus areas. "While consumer, healthcare and financial services remain the bulk of our portfolio today, we are also trying to build our expertise in industrials and newer sub-sectors like space-tech," Vishesh Shrivastav, managing director at Temasek India, told Mint.
This shift toward industrials, infrastructure, and renewables reflects India's manufacturing push and energy transition opportunities. It also provides portfolio balance—adding cyclical exposure to defensive consumer and healthcare holdings.
The recent IPO successes validate Temasek's early-stage investment approach. Shiprocket's IPO was subscribed 99.38 times overall, with QIBs bidding 122.80 times. The logistics company listed at 35% premium and ended the day nearly 50% above its IPO price.
Milky Mist traded at 40% above its IPO price within a day, while Molbio Diagnostics listed at 21.44% premium despite some volatility. Manipal Health, where Temasek holds a controlling 51.03% stake through three subsidiaries, maintained a steady 25% premium. RHP
Several factors enabled these strong debuts. SEBI's September 2025 IPO reforms played a crucial role. The regulator expanded anchor investor allocations to 40% and brought in insurance and pension funds, broadening the institutional investor base. New lock-in requirements—50% of anchor allocation locked for 90 days—reduced post-listing volatility.
The reforms also provided flexibility on minimum public shareholding norms for large companies and relaxed promoter ESOP rules, making it easier for startups to list while retaining key talent.
Temasek's $9 billion deployment over the past three years represents a significant acceleration from historical patterns. The firm invested $3 billion annually in FY24, FY25, and is targeting $3-4 billion in FY26.
Several factors drove this acceleration. First, India emerged as Temasek's best-performing market globally, validating the thesis and encouraging increased deployment. Second, Temasek became more cautious on China due to geopolitical tensions and regulatory changes, redirecting capital to India. Third, India's capital markets deepened significantly, enabling larger transactions and better exit opportunities.
The team expansion also mattered. Temasek's India team grew from limited presence to 20+ investment professionals, supporting increased deal flow and execution capability.
The recent improvement in foreign investment flows—Kotak Mahindra Asset Management Singapore noted flows are "better now than three months ago"—suggests the market may be turning. This could create both opportunities and challenges for Temasek.
On one hand, better market conditions facilitate IPO exits and secondary market sales. On the other, increased foreign investor participation may drive up valuations and increase competition for quality assets.
Temasek's strategy going forward will likely focus on three areas: continuing to add to high-conviction positions during volatility, expanding into new sectors like industrials and renewables, and leveraging its early-stage investment expertise to identify the next generation of Indian unicorns.
The firm's ability to remain patient while others panic, to see structural trends where others see cyclical risks, and to execute with conviction when markets are fearful—these are the qualities that turned India into Temasek's best-performing market. As the sovereign wealth fund continues its India journey, the question isn't whether it will keep deploying capital, but where it will find the next Shiprockets, Milky Mists, and Molbio Diagnostics.
